Bolt Biotherapeutics (NASDAQ:BOLT) Given New $1.25 Price Target at Stifel Nicolaus

Bolt Biotherapeutics (NASDAQ:BOLT) had its price objective dropped by stock analysts at Stifel Nicolaus from $1.50 to $1.25 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has a “hold” rating on the stock. Stifel Nicolaus’ price objective indicates a potential upside of 185.65% from the stock’s previous close.

Bolt Biotherapeutics Price Performance

BOLT opened at $0.44 on Tuesday. The company has a market capitalization of $16.75 million, a P/E ratio of -0.26 and a beta of 0.94. The company has a 50-day moving average of $0.47 and a 200-day moving average of $0.56. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. Bolt Biotherapeutics has a 1-year low of $0.38 and a 1-year high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.79 million. Equities analysts expect that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter valued at $42,000. Velan Capital Investment Management LP acquired a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth about $27,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics in the 4th quarter valued at about $26,000. Millennium Management LLC acquired a new position in Bolt Biotherapeutics during the 4th quarter valued at about $25,000. Finally, FMR LLC boosted its stake in Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.